Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS


Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.

The conversation concludes with each participant offering insights and advice regarding the use of NTCD-20 therapies in clinical practice. The speaker emphasizes the importance of reassurance for newly diagnosed patients, highlighting the evolving nature of research and the wealth of data available to inform long-term treatment decisions.

The speaker underscores the positive outcomes observed in patients on NTCD-20 medications but highlights the need for further research, especially regarding older patients and rare complications. She emphasizes the importance of personalized medicine and the need for clarity on treatment duration and discontinuation protocols.

The speaker echoes the sentiment of reassurance for patients and emphasizes the need for vigilance among prescribers, staying updated on emerging literature and monitoring patients for potential complications. She also highlights the need for precision medicine approaches in multiple sclerosis (MS) treatment.

The speaker adds to the discussion by emphasizing the need for long-term studies to assess the impact of NTCD-20 therapies on disease progression, particularly in patients with late-onset MS. She advocates for personalized medicine and the development of biomarkers to guide treatment decisions.

Overall, the conversation highlights the importance of staying informed, reassurance for patients, and the need for precision medicine approaches in MS treatment. The participants express gratitude for the discussion and hope that it proves useful and informative to the audience.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
Valerie J. Block, PT, DPTSc
Patricia K. Coyle, MD
Video 2 - 5 KOLs are featured in "Natural History of Spinal Muscular Atrophy"
Video 1 - 5 KOLs are featured in "Clinical Features and Phenotypes of Spinal Muscular Atrophy"
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
Kathy Zackowski, PhD, OTR
A panel of 3 experts on Alzheimer's disease
A panel of 3 experts on Alzheimer's disease
Jenn Orthmann-Murphy, MD, PhD
Anthony Feinstein, MPhil, PhD
© 2024 MJH Life Sciences

All rights reserved.